$10.15
0.121.20%
At Close: -
$10.15
00.00%
After Hours: 5:08 PM EDT
15 minutes delayed
Comments
Loading...
Vir Biotechnology
VIRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Vir Biotechnology (NASDAQ:VIR) Stock, Analyst Ratings, Price Targets, Forecasts
Vir Biotechnology Inc has a consensus price target of $32.92 based on the ratings of 12 analysts. The high is $110 issued by HC Wainwright & Co. on June 5, 2024. The low is $12 issued by JP Morgan on May 3, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, HC Wainwright & Co., and Needham on June 6, 2024, June 5, 2024, and June 5, 2024, respectively. With an average price target of $48 between Morgan Stanley, HC Wainwright & Co., and Needham, there's an implied 372.91% upside for Vir Biotechnology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
HC Wainwright & Co.
Needham
JP Morgan
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Vir Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/06/2024 | Buy Now | 47.78% | Morgan Stanley | Michelle Gilson | $12 → $15 | Maintains | Equal-Weight | Get Alert |
| 06/05/2024 | Buy Now | 983.74% | HC Wainwright & Co. | Patrick Trucchio | $110 → $110 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 87.19% | Needham | Joseph Stringer | $15 → $19 | Maintains | Buy | Get Alert |
| 05/24/2024 | Buy Now | 983.74% | HC Wainwright & Co. | Patrick Trucchio | → $110 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 983.74% | HC Wainwright & Co. | Patrick Trucchio | → $110 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 47.78% | Needham | Joseph Stringer | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 18.23% | JP Morgan | Eric Joseph | $10 → $12 | Maintains | Neutral | Get Alert |
| 03/15/2024 | Buy Now | 983.74% | HC Wainwright & Co. | Patrick Trucchio | → $110 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -1.48% | JP Morgan | Eric Joseph | $9 → $10 | Maintains | Neutral | Get Alert |
| 02/14/2024 | Buy Now | 983.74% | HC Wainwright & Co. | Patrick Trucchio | $85 → $110 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | -11.33% | JP Morgan | Eric Joseph | $23 → $9 | Downgrade | Overweight → Neutral | Get Alert |
| 01/23/2024 | Buy Now | 737.44% | HC Wainwright & Co. | Patrick Trucchio | $95 → $85 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 47.78% | Needham | Joseph Stringer | $22 → $15 | Maintains | Buy | Get Alert |
| 09/08/2023 | Buy Now | 37.93% | B of A Securities | Geoff Meacham | $23 → $14 | Downgrade | Buy → Neutral | Get Alert |
| 08/07/2023 | Buy Now | 835.96% | HC Wainwright & Co. | Patrick Trucchio | $100 → $95 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 116.75% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 47.78% | Morgan Stanley | Michelle Gilson | $27 → $15 | Maintains | Equal-Weight | Get Alert |
| 07/21/2023 | Buy Now | 175.86% | Goldman Sachs | Paul Choi | $51 → $28 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 303.94% | Barclays | Gena Wang | $59 → $41 | Maintains | Overweight | Get Alert |
| 07/20/2023 | Buy Now | 116.75% | Needham | Joseph Stringer | $32 → $22 | Maintains | Buy | Get Alert |
| 07/20/2023 | Buy Now | 885.22% | HC Wainwright & Co. | Patrick Trucchio | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 215.27% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 215.27% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
| 04/04/2023 | Buy Now | 166.01% | Morgan Stanley | Michelle Gilson | $25 → $27 | Maintains | Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 885.22% | HC Wainwright & Co. | Patrick Trucchio | $125 → $100 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 234.98% | JP Morgan | Eric Joseph | $35 → $34 | Upgrade | Neutral → Overweight | Get Alert |
| 02/24/2023 | Buy Now | 215.27% | Needham | Joseph Stringer | → $32 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 422.17% | Goldman Sachs | Paul Choi | $41 → $53 | Maintains | Buy | Get Alert |
| 02/21/2023 | Buy Now | 422.17% | Goldman Sachs | Paul Choi | $41 → $53 | Upgrade | Neutral → Buy | Get Alert |
| 01/27/2023 | Buy Now | 323.65% | SVB Leerink | Roanna Ruiz | $45 → $43 | Maintains | Outperform | Get Alert |
| 01/27/2023 | Buy Now | 195.57% | Morgan Stanley | Michael Ulz | $18 → $30 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | 77.34% | Morgan Stanley | Andrew Galler | $15 → $18 | Maintains | Underweight | Get Alert |
| 11/04/2022 | Buy Now | 215.27% | Needham | Joseph Stringer | $35 → $32 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 343.35% | SVB Leerink | Roanna Ruiz | $40 → $45 | Maintains | Outperform | Get Alert |
| 09/14/2022 | Buy Now | 294.09% | SVB Leerink | Roanna Ruiz | → $40 | Initiates | → Outperform | Get Alert |
| 09/09/2022 | Buy Now | 47.78% | Morgan Stanley | Andrew Galler | → $15 | Initiates | → Underweight | Get Alert |
| 05/12/2022 | Buy Now | 1131.53% | HC Wainwright & Co. | Patrick Trucchio | $200 → $125 | Maintains | Buy | Get Alert |
| 05/06/2022 | Buy Now | 244.83% | Needham | Joseph Stringer | $45 → $35 | Maintains | Buy | Get Alert |
| 03/30/2022 | Buy Now | 1870.44% | HC Wainwright & Co. | Patrick Trucchio | $300 → $200 | Maintains | Buy | Get Alert |
| 03/28/2022 | Buy Now | 343.35% | Needham | Joseph Stringer | $80 → $45 | Maintains | Buy | Get Alert |
| 03/03/2022 | Buy Now | 175.86% | Baird | Joel Beatty | $36 → $28 | Upgrade | Underperform → Neutral | Get Alert |
| 12/21/2021 | Buy Now | 254.68% | Baird | Joel Beatty | → $36 | Downgrade | Neutral → Underperform | Get Alert |
| 12/21/2021 | Buy Now | 2855.67% | HC Wainwright & Co. | Patrick Trucchio | $200 → $300 | Maintains | Buy | Get Alert |
| 11/30/2021 | Buy Now | 1870.44% | HC Wainwright & Co. | Patrick Trucchio | — | Maintains | Buy | Get Alert |
| 10/25/2021 | Buy Now | 264.53% | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
| 09/22/2021 | Buy Now | 510.84% | Goldman Sachs | Paul Choi | — | Downgrade | Buy → Neutral | Get Alert |
| 08/06/2021 | Buy Now | 599.51% | Barclays | Gena Wang | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Vir Biotechnology (VIR) stock?
The latest price target for Vir Biotechnology (NASDAQ:VIR) was reported by Morgan Stanley on June 6, 2024. The analyst firm set a price target for $15.00 expecting VIR to rise to within 12 months (a possible 47.78% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vir Biotechnology (VIR)?
The latest analyst rating for Vir Biotechnology (NASDAQ:VIR) was provided by Morgan Stanley, and Vir Biotechnology maintained their equal-weight rating.
When was the last upgrade for Vir Biotechnology (VIR)?
The last upgrade for Vir Biotechnology Inc happened on March 6, 2023 when JP Morgan raised their price target to $34. JP Morgan previously had a neutral for Vir Biotechnology Inc.
When was the last downgrade for Vir Biotechnology (VIR)?
The last downgrade for Vir Biotechnology Inc happened on January 29, 2024 when JP Morgan changed their price target from $23 to $9 for Vir Biotechnology Inc.
When is the next analyst rating going to be posted or updated for Vir Biotechnology (VIR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vir Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vir Biotechnology was filed on June 6, 2024 so you should expect the next rating to be made available sometime around June 6, 2025.
Is the Analyst Rating Vir Biotechnology (VIR) correct?
While ratings are subjective and will change, the latest Vir Biotechnology (VIR) rating was a maintained with a price target of $12.00 to $15.00. The current price Vir Biotechnology (VIR) is trading at is $10.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.